Cell Guidance Systems is developing a patented technology to unlock the medical potential of growth factor proteins. PODS enables proteins to treat diseases, such as Parkinson's disease and osteoarthritis, by improving their delivery to the disease site. The technology addresses multi-$bn markets.
Most of the world's top-selling drugs are proteins. Humira alone generated sales >$18bn in 2017 (www.statista.com).
Cell Guidance Systems, based in Cambridge at the heart of the UK biotech industry, is developing PODS (Polyhedrin Delivery System), a platform technology for sustained growth factor delivery protected by exclusively licensed patents. PODS has the potential to transform medical care for many common diseases including osteoarthritis, neurodegenerative disease (such as Parkinson’s disease and motor neuron disease), wound healing, eye disease, and cancer. PODS research also shows potential for the delivery of vaccines. Our lead programme for osteoarthritis is being developed with the University of Cambridge.
Cell Guidance Systems generated revenues of >£1m in revenue in 2017 when consolidated with revenue from its wholly owned US subsidiary, (operating at a £90k loss). Our objective is to become a leading global therapeutic protein delivery company, with therapeutic products in clinics within 3 years.
Why is delivery important?
Growth factors, a particularly potent class of proteins, guide cells to regenerate damaged tissue, but most need to be targeted by precise surgical delivery to avoid harmful side effects. Since daily surgery isn't practical and growth factors can be slow-acting and fragile, a technology providing sustained release of stabilized protein is required.